) BioNxt Advances GLP-1Sublingual Semaglutide ODFProgram with NextStage of DeliveryDevelopment Underway BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway ... Sublingual ODF.
BioNxt believes the timing is appropriate to advance commercialization planning for BNT23001, the Company's patented sublingual Cladribine ODF program for multiple sclerosis.
SAM-002 is a 24-week, multicentre, double-blind, placebo-controlled study investigating a rapid dissolving 2.5 mg minoxidil tablet, administered sublingually twice daily ...Sublingual minoxidil is a ...